Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 2714

1.

β-Blocker Use in Pregnancy and the Risk for Congenital Malformations.

Shantsila A, Beevers DG, Lip GYH.

Ann Intern Med. 2019 Jun 18;170(12):909. doi: 10.7326/L19-0156. No abstract available.

PMID:
31207629
2.

Letter by Guo et al Regarding Article, "Effectiveness of an mHealth-Based Electronic Decision Support System for Integrated Management of Chronic Conditions in Primary Care: The mWellcare Cluster-Randomized Controlled Trial".

Guo Y, Lip GYH, Potpara T.

Circulation. 2019 Jun 11;139(24):e1037-e1038. doi: 10.1161/CIRCULATIONAHA.118.038961. Epub 2019 Jun 10. No abstract available.

PMID:
31180748
3.

Response.

Lip GYH, Ruff CT, Moores L; 2018 CHEST Guideline Expert Panel.

Chest. 2019 Jun;155(6):1311-1312. doi: 10.1016/j.chest.2019.03.037. No abstract available.

PMID:
31174653
4.

Response.

Lip GYH, Ruff CT, Moores L; 2018 CHEST Guideline Expert Panel.

Chest. 2019 Jun;155(6):1309. doi: 10.1016/j.chest.2019.03.001. No abstract available.

PMID:
31174651
5.

Response.

Lip GYH, Ruff CT, Moores L; 2018 CHEST guideline Expert Panel.

Chest. 2019 Jun;155(6):1307. doi: 10.1016/j.chest.2019.02.329. No abstract available.

PMID:
31174649
6.

Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices.

Pastori D, Miyazawa K, Li Y, Székely O, Shahid F, Farcomeni A, Lip GYH.

Clin Res Cardiol. 2019 May 29. doi: 10.1007/s00392-019-01493-z. [Epub ahead of print]

PMID:
31144064
7.

Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity-Weighted Cohort Study.

Søgaard M, Skjøth F, Jensen M, Kjældgaard JN, Lip GYH, Larsen TB, Nielsen PB.

J Am Heart Assoc. 2019 Jun 4;8(11):e011358. doi: 10.1161/JAHA.118.011358. Epub 2019 May 29.

8.

Renal function and outcomes after catheter ablation of patients with atrial fibrillation: The Guangzhou atrial fibrillation ablation registry.

Deng H, Shantsila A, Xue Y, Bai Y, Guo P, Potpara TS, Zhan X, Fang X, Liao H, Wu S, Lip GYH.

Arch Cardiovasc Dis. 2019 May 24. pii: S1875-2136(19)30097-X. doi: 10.1016/j.acvd.2019.02.006. [Epub ahead of print]

PMID:
31133543
9.

Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism.

Zeng J, Zhang X, Lip GYH, Shu X, Thabane L, Tian J, Li G.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619853629. doi: 10.1177/1076029619853629.

PMID:
31132874
10.

Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies.

Wilson D, Ambler G, Lee KJ, Lim JS, Shiozawa M, Koga M, Li L, Lovelock C, Chabriat H, Hennerici M, Wong YK, Mak HKF, Prats-Sánchez L, Martínez-Domeño A, Inamura S, Yoshifuji K, Arsava EM, Horstmann S, Purrucker J, Lam BYK, Wong A, Kim YD, Song TJ, Schrooten M, Lemmens R, Eppinger S, Gattringer T, Uysal E, Tanriverdi Z, Bornstein NM, Assayag EB, Hallevi H, Tanaka J, Hara H, Coutts SB, Hert L, Polymeris A, Seiffge DJ, Lyrer P, Algra A, Kappelle J, Al-Shahi Salman R, Jäger HR, Lip GYH, Mattle HP, Panos LD, Mas JL, Legrand L, Karayiannis C, Phan T, Gunkel S, Christ N, Abrigo J, Leung T, Chu W, Chappell F, Makin S, Hayden D, Williams DJ, Kooi ME, van Dam-Nolen DHK, Barbato C, Browning S, Wiegertjes K, Tuladhar AM, Maaijwee N, Guevarra C, Yatawara C, Mendyk AM, Delmaire C, Köhler S, van Oostenbrugge R, Zhou Y, Xu C, Hilal S, Gyanwali B, Chen C, Lou M, Staals J, Bordet R, Kandiah N, de Leeuw FE, Simister R, van der Lugt A, Kelly PJ, Wardlaw JM, Soo Y, Fluri F, Srikanth V, Calvet D, Jung S, Kwa VIH, Engelter ST, Peters N, Smith EE, Yakushiji Y, Orken DN, Fazekas F, Thijs V, Heo JH, Mok V, Veltkamp R, Ay H, Imaizumi T, Gomez-Anson B, Lau KK, Jouvent E, Rothwell PM, Toyoda K, Bae HJ, Marti-Fabregas J, Werring DJ; Microbleeds International Collaborative Network.

Lancet Neurol. 2019 Jul;18(7):653-665. doi: 10.1016/S1474-4422(19)30197-8. Epub 2019 May 23.

11.

Revisiting the risks of incident atrial fibrillation: a narrative review. Part 2.

Panchal G, Mahmood M, Lip GYH.

Kardiol Pol. 2019 May 24;77(5):515-524. doi: 10.33963/KP.14846. Epub 2019 May 24.

12.

Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.

Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia Reeves AB, Yuce H, Lip GYH.

J Am Geriatr Soc. 2019 May 21. doi: 10.1111/jgs.15956. [Epub ahead of print]

PMID:
31112292
13.

Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.

Chan YH, Lee HF, See LC, Tu HT, Chao TF, Yeh YH, Wu LS, Kuo CT, Chang SH, Lip GYH.

Chest. 2019 May 16. pii: S0012-3692(19)31056-6. doi: 10.1016/j.chest.2019.04.108. [Epub ahead of print]

PMID:
31103697
14.

CaseReport: Aldosterone-secreting adrenal carcinoma complicating longstanding hypertension.

Shantsila A, Lip GYH, Beevers DG.

J Hum Hypertens. 2019 May 14. doi: 10.1038/s41371-019-0209-8. [Epub ahead of print] No abstract available.

PMID:
31089198
15.

Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function.

Lee SR, Choi EK, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH.

Stroke. 2019 Jun;50(6):1480-1489. doi: 10.1161/STROKEAHA.118.024264. Epub 2019 May 14.

PMID:
31084339
16.

Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores.

Rivera-Caravaca JM, Marín F, Vilchez JA, Gálvez J, Esteve-Pastor MA, Vicente V, Lip GYH, Roldán V.

Stroke. 2019 Jun;50(6):1372-1379. doi: 10.1161/STROKEAHA.118.024305. Epub 2019 May 14.

PMID:
31084333
17.

Short-Term Outcomes of Apixaban Versus Warfarin in Patients With Atrial Fibrillation.

Lip GYH, Khan AA, Olshansky B.

Circulation. 2019 May 14;139(20):2301-2303. doi: 10.1161/CIRCULATIONAHA.119.040021. No abstract available.

PMID:
31082294
18.

Association Between Digoxin Use and Adverse Outcomes Among Patients in the Chinese Atrial Fibrillation Registry.

Gao Y, Chang S, Du X, Dong J, Xu X, Zhou Y, Lip GYH, Ma C.

Am J Cardiovasc Drugs. 2019 May 11. doi: 10.1007/s40256-019-00350-8. [Epub ahead of print]

PMID:
31077081
19.

Editorial commentary: Reversal agents in the era of non-vitamin k antagonists oral anticoagulants: Necessity or psychological crutch?

Dzeshka MS, Lip GYH.

Trends Cardiovasc Med. 2019 Apr 27. pii: S1050-1738(19)30052-0. doi: 10.1016/j.tcm.2019.04.007. [Epub ahead of print] No abstract available.

PMID:
31072696
20.

Time-dependent prediction of arrhythmia recurrences during long-term follow-up in patients undergoing catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry.

Kornej J, Schumacher K, Zeynalova S, Sommer P, Arya A, Weiß M, Piorkowski C, Husser D, Bollmann A, Lip GYH, Hindricks G.

Sci Rep. 2019 May 8;9(1):7112. doi: 10.1038/s41598-019-43644-2.

21.

Atrial Fibrillation and End-Stage COPD: A Close Association Revisited.

Shin SY, Manuel ARG, Lip GYH.

Chest. 2019 May;155(5):888-889. doi: 10.1016/j.chest.2019.01.027. No abstract available.

PMID:
31060700
22.

Long-Term Impact of Newly Diagnosed Atrial Fibrillation During Critical Care: A South Korean Nationwide Cohort Study.

Kim K, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, Lip GYH, Joung B.

Chest. 2019 Apr 30. pii: S0012-3692(19)30876-1. doi: 10.1016/j.chest.2019.04.011. [Epub ahead of print]

PMID:
31051171
23.

Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation.

Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH.

Sci Rep. 2019 Apr 30;9(1):6690. doi: 10.1038/s41598-019-43224-4.

24.

Monocyte-platelet cross-talk in peripheral artery disease-how much does the pathogenesis of atherosclerosis depend on anatomical location?

Brown RA, Lip GYH.

Ann Transl Med. 2019 Mar;7(Suppl 1):S19. doi: 10.21037/atm.2019.01.47. No abstract available.

25.

Atrial high-rate episodes and thromboembolism in patients without atrial fibrillation: The West Birmingham Atrial Fibrillation Project.

Li YG, Miyazawa K, Pastori D, Szekely O, Shahid F, Lip GYH.

Int J Cardiol. 2019 Apr 17. pii: S0167-5273(19)31387-7. doi: 10.1016/j.ijcard.2019.04.055. [Epub ahead of print]

PMID:
31031080
26.

Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines.

Proietti M, Lane DA, Boriani G, Lip GYH.

Can J Cardiol. 2019 May;35(5):619-633. doi: 10.1016/j.cjca.2019.02.009. Epub 2019 Feb 21. Review.

PMID:
31030864
27.

Importance of Risk Reassessment in Patients With Atrial Fibrillation in Guidelines: Assessing Risk as a Dynamic Process.

Chang TY, Lip GYH, Chen SA, Chao TF.

Can J Cardiol. 2019 May;35(5):611-618. doi: 10.1016/j.cjca.2019.01.018. Epub 2019 Feb 2. Review.

PMID:
31030863
28.

Guideline Implications of Prothrombotic State Assessment in Low-Risk Atrial Fibrillation Patients: Consistency With CHA2DS2-VASc and Support for CHADS-65.

Nattel S, Lip GYH.

Can J Cardiol. 2019 May;35(5):547-549. doi: 10.1016/j.cjca.2019.03.001. Epub 2019 Mar 8. No abstract available.

PMID:
31030855
29.

Revisiting the risks of incident atrial fibrillation: a narrative review. Part 1.

Panchal G, Mahmood M, Lip GYH.

Kardiol Pol. 2019 Apr 18;77(4):430-436. doi: 10.33963/KP.14806. Epub 2019 Apr 25.

30.

Microparticles and cardiovascular diseases.

Voukalis C, Shantsila E, Lip GYH.

Ann Med. 2019 Jun 17:1-31. doi: 10.1080/07853890.2019.1609076. [Epub ahead of print]

PMID:
31007084
31.

Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF-App) II randomised trial.

Guo Y, Lane DA, Wang L, Chen Y, Lip GYH; mAF-App II Trial investigators.

Int J Clin Pract. 2019 Apr 19:e13352. doi: 10.1111/ijcp.13352. [Epub ahead of print]

PMID:
31002434
32.

Galectin-3 and β-trace protein concentrations are higher in clinically unaffected patients with Fabry disease.

Hernández-Romero D, Sánchez-Quiñones J, Vílchez JA, Rivera-Caravaca JM, de la Morena G, Lip GYH, Climent V, Marín F.

Sci Rep. 2019 Apr 17;9(1):6235. doi: 10.1038/s41598-019-42727-4.

33.

Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus.

Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GYH, Jensen MB.

Circ Arrhythm Electrophysiol. 2019 May;12(5):e007030. doi: 10.1161/CIRCEP.118.007030.

PMID:
30995869
34.

Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry.

Liu C, Du X, Jiang C, He L, Chang SS, Guo XY, Yu RH, Long DY, Bai R, Liu N, Sang CH, Jiang CX, Dong JZ, Lip GYH, Ma CS.

Med Sci Monit. 2019 Apr 11;25:2649-2657. doi: 10.12659/MSM.915875.

35.

Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a Nationwide Population Study.

Park J, Choi EK, Han KD, Choi YJ, Lee SR, Cha MJ, Kang J, Park KW, Oh S, Lip GYH.

Am J Cardiol. 2019 Jun 15;123(12):1921-1926. doi: 10.1016/j.amjcard.2019.03.024. Epub 2019 Mar 16.

PMID:
30967291
36.

To the Editor- Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?

Joung B, Lip GYH.

Heart Rhythm. 2019 Apr 4. pii: S1547-5271(19)30306-6. doi: 10.1016/j.hrthm.2019.04.006. [Epub ahead of print] No abstract available.

PMID:
30954602
37.

Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation.

Fawzy AM, Lip GYH.

Expert Opin Drug Metab Toxicol. 2019 May;15(5):381-398. doi: 10.1080/17425255.2019.1604686. Epub 2019 Apr 19. Review.

PMID:
30951640
38.

Stroke: Insights into Thromboembolism Treatment and Prevention through the Decades.

Ntaios G, Lip GYH.

Thromb Haemost. 2019 May;119(5):685-687. doi: 10.1055/s-0039-1685454. Epub 2019 Apr 4. No abstract available.

PMID:
30947348
39.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

Proietti M, Farcomeni A, Goethals P, Scavee C, Vijgen J, Blankoff I, Vandekerckhove Y, Lip GY, Mairesse GH; Belgian Heart Rhythm Week Investigators.

Eur J Prev Cardiol. 2019 Jun;26(9):964-972. doi: 10.1177/2047487319839184. Epub 2019 Apr 1.

PMID:
30935219
40.

Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study.

Bonde AN, Blanche P, Staerk L, Gerds TA, Gundlund A, Gislason G, Torp-Pedersen C, Lip GYH, Hlatky MA, Olesen JB.

Eur Heart J. 2019 Apr 1. pii: ehz155. doi: 10.1093/eurheartj/ehz155. [Epub ahead of print]

PMID:
30932145
41.

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.

Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP.

Am Heart J. 2019 Jun;212:13-22. doi: 10.1016/j.ahj.2019.02.006. Epub 2019 Mar 1.

PMID:
30928824
42.

Safety of drug-eluting stents compared to bare metal stents in patients with an indication for long-term oral anticoagulation: A propensity score matched analysis.

Limeres J, Lip GYH, Del Blanco BG, Ferreira-González I, Mutuberria M, Alfonso F, Bueno H, Cequier A, Prendergast B, Zueco J, Rodríguez-Leor O, Barrabés JA, García-Dorado D, Sambola A.

Thromb Res. 2019 May;177:180-186. doi: 10.1016/j.thromres.2019.02.021. Epub 2019 Mar 14.

PMID:
30925398
43.

Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function.

Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH.

Stroke. 2019 May;50(5):1140-1148. doi: 10.1161/STROKEAHA.118.024210.

PMID:
30913984
44.

Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry.

Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF Long-Term General Registry Investigators.

Europace. 2019 Mar 24. pii: euz032. doi: 10.1093/europace/euz032. [Epub ahead of print]

PMID:
30904925
45.

Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients.

Chao TF, Liao JN, Tuan TC, Lin YJ, Chang SL, Lo LW, Hu YF, Chung FP, Chen TJ, Lip GYH, Chen SA.

Thromb Haemost. 2019 Mar 21. doi: 10.1055/s-0039-1683933. [Epub ahead of print]

PMID:
30900222
46.

The Liverpool Centre for Cardiovascular Science.

Lip GYH, Lane DA.

Eur Heart J. 2019 Mar 21;40(12):957-958. doi: 10.1093/eurheartj/ehz107. No abstract available.

PMID:
30896770
47.

Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association.

Temporelli PL, Tilz RR, Arbelo E, Dagres N, Laroche C, Crijns HJ, Blomstrom-Lundqvist C, Kirchhof P, Lip GYH, Boriani G, Pokushalov E, Nakou E, Brugada J, Tavazzi L.

Eur J Heart Fail. 2019 May;21(5):690-693. doi: 10.1002/ejhf.1458. Epub 2019 Mar 21. No abstract available.

PMID:
30896056
48.

Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis.

Petryszyn P, Niewinski P, Staniak A, Piotrowski P, Well A, Well M, Jeskowiak I, Lip G, Ponikowski P.

PLoS One. 2019 Mar 20;14(3):e0213198. doi: 10.1371/journal.pone.0213198. eCollection 2019.

49.

Predicting stroke in patients without atrial fibrillation.

Steensig K, Olesen KKW, Thim T, Nielsen JC, Madsen M, Jensen SE, Jensen LO, Kristensen SD, Lip GYH, Maeng M.

Eur J Clin Invest. 2019 Mar 18:e13103. doi: 10.1111/eci.13103. [Epub ahead of print]

PMID:
30883728
50.

EHRA White Paper: knowledge gaps in arrhythmia management-status 2019.

Goette A, Auricchio A, Boriani G, Braunschweig F, Terradellas JB, Burri H, Camm AJ, Crijns H, Dagres N, Deharo JC, Dobrev D, Hatala R, Hindricks G, Hohnloser SH, Leclercq C, Lewalter T, Lip GYH, Merino JL, Mont L, Prinzen F, Proclemer A, Pürerfellner H, Savelieva I, Schilling R, Steffel J, van Gelder IC, Zeppenfeld K, Zupan I, Heidbüchel H; ESC Scientific Document Group .

Europace. 2019 Mar 18. pii: euz055. doi: 10.1093/europace/euz055. [Epub ahead of print]

PMID:
30882143

Supplemental Content

Support Center